EVERSION Technologies funding round brings in €2.3M for smart insoles

EVERSION Technologies funding has reached a new €2.3 million Seed II round, giving the Konstanz-based medtech startup more capital to expand its corrective insole system. The company said the round was led by Kammerer Holding and the Chancenkapitalfonds der Kreissparkasse Biberach, with valuation, revenue and headcount undisclosed.

The financing follows a January 2025 seed round that brought in a seven-figure amount and was also led by Kreissparkasse Biberach. EVERSION said that after that earlier raise it completed product development, scaled production and pursued medical device approval.

Other investors in the latest round include Start-up BW Seed Fonds, S-Kap Unternehmensbeteiligungsgesellschaft, Meerkat, Turtle and angel investors from the Heimatboost, BACB and hivn networks. EVERSION said it now has more than 1,500 customers.

What does EVERSION Technologies do?

EVERSION makes custom corrective insoles built from movement data. Customers wear sensor insoles and use an app for two weeks, after which EVERSION uses the collected data to create a 3D biomechanical model and manufacture an insole tailored to the user.

The company says its “0°-sole” is designed to address misalignment linked to footwear and movement patterns. According to EVERSION, the lower side of the insole adjusts loading based on user data, while the upper side lets the foot keep moving naturally.

The startup was founded in 2022 by CEO Julia Zimmermann and orthopaedic master shoemaker Wolfgang Triebstein after Zimmermann’s own hip pain was traced to her shoes. EVERSION is led by Zimmermann, Triebstein, Timon Sutter, Maximilian Starkmann and Lucas Heitele, with experience spanning engineering, computer science, orthopaedic shoemaking and sports science.

The company points to musculoskeletal disorders as the top driver of sick leave in Germany, accounting for roughly one in four absences. EVERSION claims poorly suited shoes can contribute to misalignment and pain in the knees, hips and back.

Why does German insurer coverage matter?

Reimbursement gives EVERSION a commercial foothold that many early medtech hardware companies spend years trying to secure. By the end of 2025, the company said it had CE certification as a medical device, had launched the product and had obtained reimbursement coverage.

EVERSION said German statutory health insurers cover the product through a prevention-course program regulated by the Zentrale Prüfstelle Prävention. Privately insured patients can receive reimbursement with a prescription, according to the company.

That positioning separates EVERSION from several companies working on adjacent gait and movement-analysis products. Munich-based Moticon sells sensor insoles for research and elite sports use. France’s Digitsole has raised about $2.2 million for consumer smart footwear. Canada’s Orpyx focuses on clinical reimbursement for diabetic foot ulcer prevention.

EVERSION is targeting broader consumer health and prevention, selling directly to users while also building clinical referral channels. The company’s next task is turning early reimbursement access into repeatable distribution through doctors, therapists and orthopaedic supply stores.

What will EVERSION use the new money for?

The startup said the €2.3 million will go toward sales, marketing and partnerships with doctors, therapists and orthopaedic supply stores. It also said it wants to increase public understanding of how footwear, gait and pain may be connected.

The category has room for more capital. Coherent Market Insights expects the global gait-analysis systems market to reach about $3 billion in 2026 and $5.72 billion by 2033, implying a 9.6% annual growth rate. EVERSION’s early reimbursement status is the main strategic asset disclosed in the round. The open question for operators and investors is whether that approval becomes a defensible channel advantage before larger orthopaedic or insurtech players move into reimbursed prevention.

This story draws on original reporting from TechFundingNews.